Season 1 · Episode 36
E36: Patients First? Why Pharma Sleeping on GenAI Costs Lives
The AI Cookbook: AI Tools | Enterprise AI | Leadership · Malcolm Werchota
August 9, 202520m 31sExplicit
Audio is streamed directly from the publisher (api.riverside.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The most uncomfortable 20 minutes in pharma this year: How GenAI achieves 90% drug discovery success while you're at 0.01%.
Verified facts from yesterday's Nature paper and last week's industry announcements.
Breaking down:
- 8 successful cancer drug candidates from 9 attempts (published yesterday, peer-reviewed)
- Traditional Phase 2 success: 28-40% | AI-enhanced: 89% (CDK2 target Pfizer couldn't crack)
- 1 billion molecular evaluations per week vs your 1,000 per year
- "Novel scaffolds": How AI generates entirely new patent families (20-year monopolies)
- The companies already shipping: Atomwise, BenevolentAI, Recursion (with Phase 2 proof)
- Why "it's not our core competency" is a death sentence for your pipeline
Plus: The 6-month committee meeting that costs 500 cancer patients their lives.
Every day you "observe further" is a day your competitors get closer to making you obsolete.